IPO Listed — 01 Sep 2026
Listing Price: ₹99
ABH Healthcare SME IPO GMP History | Listing Price ₹99 & Kostak Rate
ABH Healthcare SME IPO has been listed on September 1, 2026 at a listing price of ₹99, against the issue price of ₹102 — a loss of ₹3 (-2.94%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
ABH Healthcare SME IPO raised ₹34.98 Cr. through its IPO at a price band of ₹96 to ₹102 per share, with a lot size of 1200 shares. The IPO was open for subscription from 24 Aug 2026 to 27 Aug 2026.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
ABH Healthcare SME IPO Dates
| Event | Date |
|---|---|
| Open Date | 24 Aug, 2026 |
| Close Date | 27 Aug, 2026 |
| Allotment Date | 27 Aug, 2026 |
| Refund Date | 28 Aug, 2026 |
| Credit to Demat | 28 Aug, 2026 |
| Listing Date | 01 Sep, 2026 |
ABH Healthcare SME IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹102 |
| Actual Listing Price | ₹99 (-2.94%) |
| Listing Gain / Loss | ₹-3 per share |
| Listing Date | 01 Sep, 2026 |
Is ABH Healthcare SME IPO GMP Reliable?
Grey market premium for ABH Healthcare SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the ABH Healthcare SME IPO full review for a fundamentals-based assessment before making any grey market trades.
ABH Healthcare SME IPO IPO Kostak Rate Explained
The Kostak rate for ABH Healthcare SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About ABH Healthcare SME IPO
The hospital offers 25 medical specialities. These include cardiac sciences, neurology, minimally invasive spine and brain surgery, medical and surgical gastroenterology, laparoscopic and bariatric surgery, urology, pulmonology, nephrology, ENT and maxillofacial surgery.
The hospital is empanelled with 30 private and public health insurance companies and third party administrators, so patients can take cashless treatment. It also takes part in major government health schemes such as the Ex-Servicemen Contributory Health Scheme, Railways, Food Corporation of India, Bharat Sanchar Nigam Limited and Ayushman Bharat Sarbat Sehat Bima Yojana. As on 31 March 2025 it had 29 doctors and 137 nurses.
Strengths & Risks
Strengths
- ✓ The hospital covers 25 medical specialities across 150 beds, so it is not dependent on one type of treatment.
- ✓ It is empanelled with 30 private and public insurance companies and third party administrators, which brings in cashless patients.
- ✓ It takes part in major government health schemes including ECHS, Railways, Food Corporation of India, BSNL and Ayushman Bharat Sarbat Sehat Bima Yojana, which gives a steady flow of patients.
- ✓ Net worth has improved every year shown, from Rs 0.09 crore in FY2022 to Rs 4.62 crore in FY2023, Rs 6.30 crore in FY2024 and Rs 9.58 crore as on 31 December 2024.
- ✓ The hospital runs under an established local name, Anil Baghi Hospital, and is led by a doctor led management team.
- ✓ It offers advanced procedures such as minimally invasive spine and brain surgery and bariatric surgery, which usually earn better than routine treatment.
- ✓ Rs 17.00 crore of the issue money will repay borrowings, which will reduce the interest burden.
Risks
- ⚠ The financial data in the offer document is very old for an issue opening in August 2026. The latest period shown ends 31 December 2024 and is only a nine month stub, so there is no recent full year to judge the company on.
- ⚠ The figures shown are internally inconsistent. For the period ended 31 December 2024 total income is shown as Rs 3.50 crore while EBITDA is shown as Rs 8.99 crore, which cannot both be right. These numbers must be checked in the RHP before relying on them.
- ⚠ Profit has been falling year after year in the periods shown, from Rs 3.32 crore in FY2022 to Rs 1.66 crore in FY2023 and Rs 0.71 crore in FY2024.
- ⚠ Debt is very high against own funds. Total borrowing was Rs 39.67 crore as on 31 December 2024 against a net worth of only Rs 9.58 crore, which is about four times.
- ⚠ Total assets have been shrinking, from Rs 61.03 crore in FY2022 to Rs 51.35 crore in FY2023, Rs 32.96 crore in FY2024 and Rs 26.27 crore as on 31 December 2024.
- ⚠ A part of the money is kept for inorganic growth through unidentified acquisitions. The company has not named any target, so investors do not know where that money will go.
- ⚠ The whole business is one hospital, so any problem at that single location, whether staff, regulatory or reputational, affects everything.
- ⚠ Government scheme patients usually come at fixed low rates and payments can be delayed, which puts pressure on cash flow.
- ⚠ The hospital runs with 29 doctors and 137 nurses. In healthcare, patients often follow individual doctors, so losing a few key consultants can affect revenue.
- ⚠ This is an SME issue. One lot is 1,200 shares, which is about Rs 1.22 lakh at the upper band of Rs 102, and SME shares usually trade in low volume after listing.
Frequently Asked Questions about ABH Healthcare SME IPO
What is the GMP of ABH Healthcare SME IPO?
The current Grey Market Premium (GMP) of ABH Healthcare SME IPO is not yet started or active in the market.
What is the Kostak Price of ABH Healthcare SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for ABH Healthcare SME IPO is currently not available.
What is the Subject to Sauda Price of ABH Healthcare SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of ABH Healthcare SME IPO?
ABH Healthcare SME IPO listed on September 1, 2026 at ₹99, against the issue price of ₹102 — a loss of -2.94%.
How did the GMP of ABH Healthcare SME IPO trend before listing?
The GMP of ABH Healthcare SME IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore ABH Healthcare SME IPO Further
For a complete picture before making your investment decision, explore these resources:
